Oragenics, Inc. (NYSE:OGEN) recovered 26.66% of its value since hitting low of $0.38. The recent move of -3.62% drop pushed the stock to close at $0.48 when trading ended on 5/24/2019. At a recent session, the prices were hovering between $0.479 and $0.5. This company shares are 368.75% off its target price of $2.25 and the current market capitalization stands at $23.02M. The recent change has given its price a -16.1% deficit over SMA 50 and -87.13% deficit over its 52-week high. The stock witnessed -0.66% declines, -47.11% declines and -39.84% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found OGEN’s volatility during a week at 12.74% and during a month it has been found around 8%.

Oragenics, Inc. (OGEN) Top Holders

Institutional investors currently hold around $5 million or 23.9% in OGEN stock. Look at its top three institutional owners: Cvi Holdings, Llc owns $1.63 million in Oragenics, Inc., which represents roughly 7.09% of the company’s market cap and approximately 32.62% of the institutional ownership. Similar statistics are true for the second largest owner, Anson Funds Management Lp, which owns 2,980,464 shares of the stock are valued at $1.43 million. The third largest holder is Third Security, Llc, which currently holds $745 thousand worth of this stock and that ownership represents nearly 3.24% of its market capitalization.

Oragenics, Inc. 13F Filings

At the end of March reporting period, 7 institutional holders increased their position in Oragenics, Inc. (NYSE:OGEN) by some 8,289,395 shares, 4 decreased positions by 142,089 and 7 held positions by 2,597,880. That puts total institutional holdings at 11,029,364 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 8,228,902 shares while 3 institutional investors sold out their entire positions totaling 17,352 shares.

Oragenics, Inc. (NYSE:OGEN) Insider Trades

Multiple company employees have indulged in significant insider trading. Oragenics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner KOSKI FAMILY LP has acquired 169,050 shares of Oragenics, Inc. (OGEN) in the trading session dated Sep. 18, 2018. These shares are worth $71,001 and were traded at $0.42 each. The SEC filing shows that KIRK RANDAL J performed a purchase of 226,142 shares. The 10% Owner added these shares by way of transaction on Jun. 30, 2016. The company’s shares were assimilated at $5.2 per share worth to an investment of some $1,175,938 to the account of KIRK RANDAL J.

10% Owner, KOSKI FAMILY LP, purchased 1,869 common shares of Oragenics, Inc. (OGEN) in the open market. In a transaction dated Dec. 12, 2014, the shares were bought at an average price of $8.1, giving away a sum of $15,136. After this purchase, 107,052 common shares of OGEN are directly owned by the insider, with total stake valued at $51,385.

In the transaction dated Dec. 12, 2014, a great number of shares acquired came courtesy the 10% Owner; KOSKI FAMILY LP added a total of 990 shares at an average price of $8.3, amounting to approximately $8,217. The insider now directly owns 107,052 shares worth $51,385.

Oragenics, Inc. (OGEN) Analyst Guide

Several analysts have released their opinion on Oragenics, Inc. (NYSE:OGEN), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].